<SEC-DOCUMENT>0001558370-21-005794.txt : 20210505
<SEC-HEADER>0001558370-21-005794.hdr.sgml : 20210505
<ACCEPTANCE-DATETIME>20210505071031
ACCESSION NUMBER:		0001558370-21-005794
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20210505
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210505
DATE AS OF CHANGE:		20210505

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Editas Medicine, Inc.
		CENTRAL INDEX KEY:			0001650664
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				464097528
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37687
		FILM NUMBER:		21891139

	BUSINESS ADDRESS:	
		STREET 1:		11 HURLEY ST.
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02141
		BUSINESS PHONE:		617-401-9000

	MAIL ADDRESS:	
		STREET 1:		11 HURLEY ST.
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02141
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>edit-20210505x8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.7713.40453 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 5/5/2021 11:10:16 AM -->
      <!-- iXBRL Library version: 1.0.7713.40461 -->
      <!-- iXBRL Service Job ID: eef52afd-c433-4daa-b78c-798c906515df -->

  <html xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:edit="http://www.editasmedicine.com/20210505" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_5_5_2021_To_5_5_2021_MBYEzrXtsUi8fNw4j4D2GA" name="dei:EntityCentralIndexKey" id="Tc_q9dD23vZrUON_Hf75eALCA_2_1">0001650664</ix:nonNumeric><ix:nonNumeric contextRef="Duration_5_5_2021_To_5_5_2021_MBYEzrXtsUi8fNw4j4D2GA" name="dei:AmendmentFlag" id="Tc_bYrzDBsVZkiPSPtM5pTfUA_3_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="edit-20210505.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_5_5_2021_To_5_5_2021_MBYEzrXtsUi8fNw4j4D2GA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-05</xbrli:startDate><xbrli:endDate>2021-05-05</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:15.52pt;"><a id="_13de27bc_c582_42af_a8d9_75de6e6f5d06"></a><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-size:18pt;font-weight:bold;">UNITED STATES<br />SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">WASHINGTON, D.C. 20549</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:13.5pt;margin-bottom:6pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:38.36%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:18pt;font-weight:bold;text-align:center;margin:0pt 0pt 3pt 0pt;">FORM&#160;<ix:nonNumeric contextRef="Duration_5_5_2021_To_5_5_2021_MBYEzrXtsUi8fNw4j4D2GA" name="dei:DocumentType" id="Narr_pEPL-AusAEazQkJD_Tq3Vw">8-K</ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:13.5pt;margin-bottom:9pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:38.36%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">CURRENT REPORT<br />Pursuant to Section&#160;13 or 15(d)<br />of The Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><span style="font-size:10pt;white-space:pre-wrap;">Date of Report (Date of earliest event reported):  </span><ix:nonNumeric contextRef="Duration_5_5_2021_To_5_5_2021_MBYEzrXtsUi8fNw4j4D2GA" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="Narr_Au1VlgZ400KJoxoWE_ofcw"><span style="font-size:10pt;">May 5, 2021</span></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:13.5pt;margin-bottom:6pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:38.36%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:18pt;font-weight:bold;text-align:center;margin:0pt 0pt 3pt 0pt;"><ix:nonNumeric contextRef="Duration_5_5_2021_To_5_5_2021_MBYEzrXtsUi8fNw4j4D2GA" name="dei:EntityRegistrantName" id="Narr_JIbw_Qym00uNRK9VZBbOyQ">Editas Medicine, Inc.</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">(Exact Name of Registrant as Specified in its Charter)</p><div style="font-family:'Times New Roman','Times','serif';font-size:13.5pt;margin-bottom:6pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:38.36%;border:none;margin:0 auto;"><a id="_749abe8c_be64_4b17_a2ec_1ba8d064c547"></a><a id="Tc_7DMeQG8TWECsl-5DNQRA3g_2_0"></a><a id="Tc_oFIQEuTM-EW-izjOvFfgWQ_2_1"></a><a id="Tc_3YlK66ZOtkGR0WqivnKn_w_2_2"></a></div></div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:26.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:34.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:38.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_5_2021_To_5_5_2021_MBYEzrXtsUi8fNw4j4D2GA" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_xUoyjBFYkE26lDeSaJCddg_1_0"><b style="font-size:10pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:26.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_5_2021_To_5_5_2021_MBYEzrXtsUi8fNw4j4D2GA" name="dei:EntityFileNumber" id="Tc_-lHpZc4Dr0y2MKeb44oL6g_1_1"><b style="font-size:10pt;font-weight:bold;">001-37687</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:34.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_5_2021_To_5_5_2021_MBYEzrXtsUi8fNw4j4D2GA" name="dei:EntityTaxIdentificationNumber" id="Tc_DvVqKeUvs0OmElHftDtBEQ_1_2"><b style="font-size:10pt;font-weight:bold;">46-4097528</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:38.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(State or Other Jurisdiction of Incorporation)</p></td><td style="vertical-align:top;width:26.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Commission File Number)</p></td><td style="vertical-align:top;width:34.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(IRS Employer Identification No.)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_9fc645df_45fc_468e_93c2_2a55b7bda50a"></a><a id="Tc_-6dkSk5sok-WqV-yFT2hMw_1_0"></a><a id="Tc_fvt5KEDB5UOC7Be-MQBxlA_2_0"></a><a id="Tc_N7CnZuEj6E68bUlXnbr81g_2_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:45.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_5_2021_To_5_5_2021_MBYEzrXtsUi8fNw4j4D2GA" name="dei:EntityAddressAddressLine1" id="Narr_js3KQso40USdR7ZeqH-E0A"><b style="font-size:10pt;font-weight:bold;">11 Hurley Street</b></ix:nonNumeric><b style="font-size:10pt;font-weight:bold;"><br /></b><ix:nonNumeric contextRef="Duration_5_5_2021_To_5_5_2021_MBYEzrXtsUi8fNw4j4D2GA" name="dei:EntityAddressCityOrTown" id="Narr_g7TL0ow-zEO586YTQ1Xf6Q"><b style="font-size:10pt;font-weight:bold;">Cambridge</b></ix:nonNumeric><b style="font-size:10pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_5_5_2021_To_5_5_2021_MBYEzrXtsUi8fNw4j4D2GA" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="Narr_HX29x--sOk-gbibPIBlU4g"><b style="font-size:10pt;font-weight:bold;">Massachusetts</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:45.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_5_2021_To_5_5_2021_MBYEzrXtsUi8fNw4j4D2GA" name="dei:EntityAddressPostalZipCode" id="Tc_4_aWokmZHE2cubNtm1YJ2g_1_1"><b style="font-size:10pt;font-weight:bold;">02141</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:54.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Address of Principal Executive Offices)</p></td><td style="vertical-align:top;width:45.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Zip Code)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><span style="font-size:10pt;">Registrant&#8217;s telephone number, including area code:&#160;</span><b style="font-size:10pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_5_5_2021_To_5_5_2021_MBYEzrXtsUi8fNw4j4D2GA" name="dei:CityAreaCode" id="Narr_CbZuv00c20ubk9XbIIqxag"><b style="font-size:10pt;font-weight:bold;">617</b></ix:nonNumeric><b style="font-size:10pt;font-weight:bold;">)&#160;</b><ix:nonNumeric contextRef="Duration_5_5_2021_To_5_5_2021_MBYEzrXtsUi8fNw4j4D2GA" name="dei:LocalPhoneNumber" id="Narr_eT-J-PD7uUK4CIzVkQuI6Q"><b style="font-size:10pt;font-weight:bold;">401-9000</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;">(Former Name or Former Address, if Changed Since Last Report)</p><div style="font-family:'Times New Roman','Times','serif';font-size:13.5pt;margin-bottom:6pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:38.36%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<i style="font-style:italic;">see</i> General Instruction&#160;A.2. below):</p><a id="_03954c9c_0f6f_44ac_b87d_250785e27b4e"></a><a id="Tc_qyg0deFYtki_EG5tdJwElw_2_1"></a><a id="Tc_V9eQPuANREaySxP6wC1yXw_4_1"></a><a id="Tc_HtEmc8i3iEuUxxDU-uyAgA_6_1"></a><a id="Tc_MR_Q53VHy0WkVj-rYhzYYw_8_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:94.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:94.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_5_2021_To_5_5_2021_MBYEzrXtsUi8fNw4j4D2GA" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Tc_CkVI6dyNlEiX6mJd-CSbYA_2_0"><span style="font-family:'Segoe UI Symbol';font-size:10pt;">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:94.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Written communications pursuant to Rule&#160;425 under the Securities Act (17&#160;CFR&#160;230.425)</p></td></tr><tr><td style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:94.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_5_2021_To_5_5_2021_MBYEzrXtsUi8fNw4j4D2GA" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Tc_6GWmEnN4IU-dU028cxfakw_4_0"><span style="font-family:'Segoe UI Symbol';font-size:10pt;">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:94.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17&#160;CFR&#160;240.14a-12)</p></td></tr><tr><td style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:94.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_5_2021_To_5_5_2021_MBYEzrXtsUi8fNw4j4D2GA" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Tc_0AxH5jlQ-UWTIoAv-WK--Q_6_0"><span style="font-family:'Segoe UI Symbol';font-size:10pt;">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:94.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Pre-commencement communications pursuant to Rule&#160;14d-2(b) under the Exchange Act (17&#160;CFR&#160;240.14d-2(b))</p></td></tr><tr><td style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:94.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_5_2021_To_5_5_2021_MBYEzrXtsUi8fNw4j4D2GA" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Tc_vM0GyLe4oUeSMrEAiXFHcg_8_0"><span style="font-family:'Segoe UI Symbol';font-size:10pt;">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:94.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Pre-commencement communications pursuant to Rule&#160;13e-4(c) under the Exchange Act (17&#160;CFR&#160;240.13e-4(c))</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Securities registered pursuant to Section 12(b) of the Act:</p><a id="_dcb8c928_e46c_434f_a26a_0d9cf6b41806"></a><a id="Tc_ydskj6wKJUW6EzbYSSXVpw_1_0"></a><a id="Tc_MPxF8_n3DE6WHrPBVqirYw_1_1"></a><a id="Tc_XS2Aydy7a0S09a-I-1Z0PA_1_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:10pt;text-align:center;text-indent:-10pt;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:10pt;text-align:center;text-indent:-10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_5_2021_To_5_5_2021_MBYEzrXtsUi8fNw4j4D2GA" name="dei:Security12bTitle" id="Tc_6cyLafhnY0q4-fsQBtYmiQ_2_0"><span style="font-size:8pt;">Common Stock, $0.0001 par value per share</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_5_2021_To_5_5_2021_MBYEzrXtsUi8fNw4j4D2GA" name="dei:TradingSymbol" id="Tc_18dKrF0lp06X5e2LNGMT0Q_2_1"><span style="font-size:8pt;">EDIT</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_5_2021_To_5_5_2021_MBYEzrXtsUi8fNw4j4D2GA" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Tc_A54GCkrxVU-2h0ue2S1kaQ_2_2"><span style="font-size:8pt;">The Nasdaq Stock Market LLC</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-<span style="white-space:pre-wrap;">2 of this chapter).    </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:6pt 0pt 6pt 0pt;"><span style="font-size:10pt;">Emerging growth company&#160;</span><ix:nonNumeric contextRef="Duration_5_5_2021_To_5_5_2021_MBYEzrXtsUi8fNw4j4D2GA" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_Yj6orePdAUuxey9rO1j1Cg"><span style="font-family:'Segoe UI Symbol';font-size:10pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:6pt 0pt 6pt 0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.&#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span>&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;border-bottom:2.25pt double #000000;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:3pt;margin:0pt;">&#160;</p><p style="display:none;font-size:12pt;line-height:0pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_7ff353d9_bdc1_4975_b546_d4c02e256378"></a></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk535744647"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:0pt;"><b style="font-weight:bold;">Item 2.02&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b><b style="font-weight:bold;">Results of Operations and Financial Condition. </b></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On May 5, 2021, Editas Medicine, Inc. (the &#8220;Company&#8221;) issued a press release announcing financial results for the fiscal quarter ended March 31, 2021 and other business highlights. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The information contained in Item 2.02 in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed &#8220;Filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;9.01</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Financial Statements and Exhibits.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(d)&#160;Exhibits</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:10.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:87.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:10.09%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Exhibit<br />No.</b></p></td><td style="vertical-align:bottom;width:2.01%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:87.88%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td></tr><tr><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">99.1</p></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="edit-20210505xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Press release issued by the Company on May 5, 2021*</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">104</p></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background-color:#ffffff;color:#212529;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:0pt;">*&#160;&#160;&#160;This exhibit shall be deemed to be furnished and not filed.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:12pt;padding-bottom:14pt;margin:2pt 0pt 0pt 0pt;"><span style="font-size:1pt;margin-bottom:5pt;margin-top:0pt;visibility:hidden;">&#8203;</span></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;margin-bottom:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:13.5pt;visibility:hidden;">&#8203;</span></p><a id="_c68f91d4_0a5e_47c4_9879_e3084a83364b"></a></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:7.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:31.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:11.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:5.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:26.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:16.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:top;width:39.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">EDITAS MEDICINE, INC.</b></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:39.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:</p></td><td style="vertical-align:top;width:31.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">May 5, 2021</p></td><td style="vertical-align:top;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:43.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;"> /s/ Michelle Robertson</span></p></td></tr><tr><td style="vertical-align:top;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:31.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:43.25%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Michelle Robertson<br />Chief Financial Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>edit-20210505xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.10.0.88--><!--Created on: 5/5/2021 11:10:08 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Exhibit 99.1</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;"><img src="edit-20210505xex99d1001.jpg" alt="Graphic" style="display:inline-block;height:52.5pt;width:120.75pt;"></font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Editas Medicine Announces First Quarter 2021 Results and Update</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-size:12pt;font-style:italic;">Strengthening Leadership by Adding Mark S. Shearman, Ph.D., as Chief Scientific Officer</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-size:12pt;font-style:italic;">Advancing BRILLIANCE trial of EDIT-101 for LCA10; clinical data expected by year-end</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-size:12pt;font-style:italic;">RUBY trial of EDIT-301 for sickle cell disease active and recruiting</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-size:12pt;font-style:italic;">Preclinical ocular data presented at ARVO supports </i><font style="font-size:12pt;">in vivo</font><i style="font-size:12pt;font-style:italic;"> gene editing</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-size:12pt;font-style:italic;">Cash, cash equivalents, and marketable securities of </i><i style="font-size:12pt;font-style:italic;">$723 million </i><i style="font-size:12pt;font-style:italic;">as of March 31, 2021</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">CAMBRIDGE, Mass., May 5, 2021 &#8211; Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today reported business highlights and financial results for the first quarter of 2021.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;white-space:pre-wrap;">&#8220;Our team is making tremendous progress towards discovering, developing, and manufacturing novel genome editing medicines, including excellent forward momentum this quarter for our two clinical-stage medicines,&#8221; said James C. Mullen, Chairman, President and Chief Executive Officer, Editas Medicine.  &#8220;We are pleased to announce Dr. Mark Shearman will be joining Editas as Chief Scientific Officer in June 2021. Mark has an outstanding track record of drug discovery and development, and we are confident that his expertise will help us achieve our near-term milestones and continue to realize the promise of bringing transformative medicines to patients.&#8221;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Mr. Mullen continued, &#8220;In ocular, we advanced the BRILLIANCE trial of EDIT-101 for LCA10 and have line of sight for initiating the next cohort. We also presented preclinical data at ARVO that further validates our </font><i style="font-size:12pt;font-style:italic;">in vivo</i><font style="font-size:12pt;white-space:pre-wrap;"> gene editing platform in USH2A and RP4.  In </font><i style="font-size:12pt;font-style:italic;">ex vivo, </i><font style="font-size:12pt;">we advanced the RUBY trial of EDIT-301 for sickle cell disease, including activating sites for recruitment and finalizing preparations to produce study drug material for dosing patients in the trial. We look forward to maintaining the momentum through the remainder of the year and expect to share Editas&#8217; first clinical data for EDIT-101 by year-end.&#8221;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Recent Achievements and Outlook</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-style:italic;font-weight:bold;">In Vivo</font><b style="font-size:12pt;font-weight:bold;">&#160;Gene Edited Medicines</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><font style="font-family:'Symbol';">&#183;</font><font style="font-size:12pt;">&#160;&#160;&#160;&#160;</font><b style="font-size:12pt;font-weight:bold;">EDIT-101 for Leber Congenital Amaurosis 10 (LCA10)</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><i style="font-size:12pt;font-style:italic;">Initial clinical data expected by year-end</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">Editas Medicine is progressing the Phase 1/2 BRILLIANCE trial for the treatment of LCA10. The Company is continuing to dose patients in the second cohort, the adult mid-dose, and results of this cohort will inform the path to initiate dosing of pediatric patients. Clinical data from the first two cohorts is expected to be presented by the end of 2021.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><font style="font-family:'Symbol';">&#183;</font><font style="font-size:12pt;">&#160;&#160;&#160;&#160;</font><b style="font-size:12pt;font-weight:bold;">Other Ocular Programs</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><i style="font-size:12pt;font-style:italic;">Preclinical data for USH2A and RP4 presented at ARVO</i></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">Editas Medicine presented preclinical data at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting for Usher Syndrome 2A (USH2A) and retinitis pigmentosa 4 (RP4). For USH2A, the Company demonstrated that gene editing restored protein expression and rescued deficits in photoreceptor morphology in human retinal organoids. For RP4, the Company demonstrated that a dual adeno-associated virus editing system, which simultaneously knocks out and replaces the rhodopsin mutation of RP4, produced clinically relevant editing levels with no off-target editing. The Company expects to declare a development candidate for its RP4 program by the end of 2021.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-style:italic;font-weight:bold;">Ex Vivo</font><b style="font-size:12pt;font-weight:bold;"> Gene Edited Medicines</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><font style="font-family:'Symbol';">&#183;</font><font style="font-size:12pt;">&#160;&#160;&#160;&#160;</font><b style="font-size:12pt;font-weight:bold;">EDIT-301 for Sickle Cell Disease</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><i style="font-size:12pt;font-style:italic;">On track to dose first patient in RUBY trial by year-end</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">Editas Medicine is developing EDIT-301 using Cas12a (Cpf1), a proprietary enzyme, as a potentially best-in-class medicine to treat sickle cell disease. The Phase 1/2 RUBY trial for the treatment of sickle cell disease is active and recruitment of patients has started. The Company </font><font style="font-size:12pt;">remains on track </font><font style="font-size:12pt;">to begin patient dosing in the RUBY trial by the end of 2021.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><font style="font-family:'Symbol';">&#183;</font><font style="font-size:12pt;">&#160;&#160;&#160;&#160;</font><b style="font-size:12pt;font-weight:bold;">EDIT-301 for Beta-Thalassemia</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><i style="font-size:12pt;font-style:italic;">On track to file IND by year-end</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">Editas Medicine is confirming the sustained effects of EDIT-301 on cells derived from beta-thalassemia patients. The Company remains on track to file an investigational new drug application for EDIT-301 for the treatment of beta-thalassemia by the end of 2021.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Cellular Therapy</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><font style="font-family:'Symbol';">&#183;</font><font style="font-size:12pt;">&#160;&#160;&#160;&#160;</font><b style="font-size:12pt;font-weight:bold;">Edited iPSC NK (iNK) Cell Medicines to Treat Solid Tumors</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><i style="font-size:12pt;font-style:italic;">Preclinical data presented at AACR</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">Editas Medicine presented preclinical data at the American Association for Cancer Research (AACR) 2021 Annual Meeting for its iNK program to treat solid tumors. The data showed that iPSC-derived natural killer (NK) cells, edited with CRISPR/Cas12a to knockout </font><i style="font-size:12pt;font-style:italic;">CISH </i><font style="font-size:12pt;">and </font><i style="font-size:12pt;font-style:italic;">TGF&#946;R2</i><font style="font-size:12pt;">, demonstrated superior cytotoxicity and enhanced metabolic function in a tumor microenvironment, as well as improved serial killing capacity of certain tumors. These data confirm the expectation of the </font><i style="font-size:12pt;font-style:italic;">CISH </i><font style="font-size:12pt;">and </font><i style="font-size:12pt;font-style:italic;">TGF&#946;R2 </i><font style="font-size:12pt;">double knockout as a potential superior treatment for solid tumors.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><font style="font-family:'Symbol';">&#183;</font><font style="font-size:12pt;">&#160;&#160;&#160;&#160;</font><b style="font-size:12pt;font-weight:bold;">Alpha-Beta T Cells for Oncology</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><i style="font-size:12pt;font-style:italic;">Bristol Myers Squibb opting into additional program</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">Editas Medicine and Bristol Myers Squibb continue to advance alpha-beta T cell medicines for the treatment of solid and liquid tumors. Bristol Myers Squibb recently opted into an additional gene editing program, further validating the Company&#8217;s technology and expertise in engineered cell medicines.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Corporate</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><font style="font-family:'Symbol';">&#183;</font><font style="font-size:12pt;">&#160;&#160;&#160;&#160;</font><b style="font-size:12pt;font-weight:bold;">Leadership</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><a name="_Hlk71030658"></a><font style="font-size:12pt;">Today, the Company announced Mark S. Shearman, Ph.D., will be joining Editas as Chief Scientific Officer, in June 2021. Dr. Shearman has more than 30 years of experience in drug discovery and development across multiple therapeutic modalities, and his expertise in neurology, ophthalmology, and immunology will strengthen the Company&#8217;s existing pipeline. Dr. Shearman will join Editas Medicine from Applied Genetic Technologies Corporation (AGTC), where he is currently serving as Chief Scientific Officer and is responsible for leading </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">the company&#39;s product candidate selection process, pre-clinical and translational research, and long-term research and development planning. Prior to AGTC, Dr. Shearman served as Senior Vice President of Research &amp; Early Development at EMD Serono, Inc., the U.S. and Canadian subsidiary of Merck KGaA. Previously, Dr. Shearman was Executive Director of Merck &amp; Co. Research Laboratories in Boston, and Senior Director at the Merck Sharp &amp; Dohme Research Laboratories Neuroscience Research Centre in the United Kingdom. Dr. Shearman earned a B.Sc. from the University of Bristol, U.K., and a Ph.D. from the University of Nottingham, U.K. He also conducted academic research at institutes in Japan and Germany.</font><font style="font-size:12pt;"> </font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><font style="font-family:'Symbol';">&#183;</font><font style="font-size:12pt;">&#160;&#160;&#160;&#160;</font><b style="font-size:12pt;font-weight:bold;">Manufacturing</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">Editas Medicine continues to advance internal and external manufacturing capabilities for the Company&#8217;s portfolio of </font><i style="font-size:12pt;font-style:italic;">in vivo</i><font style="font-size:12pt;"> gene edited medicines, </font><i style="font-size:12pt;font-style:italic;">ex vivo</i><font style="font-size:12pt;"> gene edited cell medicines, and cell therapy medicines. The Company is finalizing the preparation of internal manufacturing capabilities for EDIT-301. This capability will provide early phase product for the RUBY trial. Concurrently, the Company has initiated the technology transfer process of EDIT-301 to its strategic CDMO partner Catalent for the later stages of the RUBY trial.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><font style="font-family:'Symbol';">&#183;</font><font style="font-size:12pt;">&#160;&#160;&#160;&#160;</font><b style="font-size:12pt;font-weight:bold;">Offering of Common Stock</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><i style="font-size:12pt;font-style:italic;">Strengthened balance sheet with net proceeds of approximately $250 million</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">Editas Medicine closed an underwritten offering of 4,025,000 shares of its common stock at a public offering price of $66.00 per share, before deducting underwriter discounts and commissions and estimated offering expenses. This included 525,000 shares issued upon exercise in full by the underwriters of their option to purchase additional shares. All shares in the offering were sold by Editas Medicine.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><font style="font-family:'Symbol';">&#183;</font><font style="font-size:12pt;">&#160;&#160;&#160;&#160;</font><b style="font-size:12pt;font-weight:bold;">Balance Sheet</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">The Company expects that its existing cash, cash equivalents and marketable securities of $723.2 million as of March 31, 2021, and anticipated interest income will enable it to fund its operating expenses and capital expenditures well into 2023.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">First Quarter for 2021 Financial Results</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Cash, cash equivalents, and marketable securities as of March 31, 2021, were $723.2 million, compared to $511.8 million as of December 31, 2020.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">For the three months ended March 31, 2021, net loss attributable to common stockholders was $56.7 million, or $0.86 per share, compared to $37.7 million, or $0.69 per share, for the same period in 2020.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><font style="font-family:'Symbol';">&#183;</font><font style="font-size:12pt;">&#160;&#160;&#160;&#160;Collaboration and other research and development revenues were $6.5 million for the three months ended March 31, 2021, compared to $5.7 million for the same period in 2020. The majority of the revenue recognized this quarter was attributable to the Company&#8217;s strategic alliance with Bristol Myers Squibb.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:left;">Research and development expenses increased by $7.3 million, to $41.9 million for the three months ended March 31, 2021, from $34.6 million for the same period in 2020. The $7.3 million increase was primarily attributable to sublicense and license fees primarily related to success payments under certain of our license agreements, as well as increased manufacturing and clinical related costs, during the first quarter of 2021. </font><font style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"><br></font><font style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:left;"> </font></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:left;">General and administrative expenses increased by $3.6 million to $21.4 million for the three months ended March 31, 2021, from $17.8 million for the same period in 2020. The $3.6 million increase was primarily attributable to increased employee-related expenses. </font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Upcoming Events</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Editas Medicine plans to participate in the following scientific and medical conferences:</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><font style="font-family:'Symbol';">&#183;</font><font style="font-size:12pt;">&#160;&#160;&#160;&#160;24th Annual Meeting of the American Society of Gene &amp; Cell Therapy (ASGCT), May 11-14, Virtual</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><font style="font-family:'Symbol';">&#183;</font><font style="font-size:12pt;">&#160;&#160;&#160;&#160;2021 World Medical Innovation Forum, May 20, Virtual</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><font style="font-family:'Symbol';">&#183;</font><font style="font-size:12pt;">&#160;&#160;&#160;&#160;European Hematology Association (EHA) 2021 Virtual Congress, June 11, Virtual</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Editas Medicine plans to participate in the following investor event:</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 8pt 18pt;"><font style="font-family:'Symbol';">&#183;</font><font style="font-size:12pt;">&#160;&#160;&#160;&#160;Raymond James Human Health Innovation Conference, June 20, Virtual</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Conference Call</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;white-space:pre-wrap;">The Editas Medicine management team will host a conference call and webcast today at 8:00 a.m. ET to provide and discuss a corporate update and financial results for the first quarter 2021.  To access the call, please dial 844-348-3801 (domestic) or 213-358-0955 (international) and provide the passcode 7587147.&#160; A live webcast of the call will be available on the Investors &amp; Media section of the Editas Medicine website at </font><font style="font-size:12pt;">www.editasmedicine.com and a replay will be available approximately two hours after its completion.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">About Editas Medicine</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">About EDIT-101</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">EDIT-101 is a CRISPR-based experimental medicine under investigation for the treatment of Leber congenital amaurosis 10 (LCA10). EDIT-101 is administered via a subretinal injection to reach and deliver the gene editing machinery directly to photoreceptor cells.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">About BRILLIANCE</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">The BRILLIANCE Phase 1/2 clinical trial of EDIT-101 for the treatment of Leber congenital amaurosis 10 (LCA10) is designed to assess the safety, tolerability, and efficacy of EDIT-101 in up to 18 patients with this disorder. Clinical trial sites are enrolling up to five cohorts testing up to three dose levels in this open label, multi-center study. Both adult and pediatric patients (3 &#8211; 17 years old) with a range of baseline visual acuity assessments are eligible for enrollment. Patients receive a single administration of EDIT-101 via subretinal injection in one eye. Additional details are available on www.clinicaltrials.gov (NCT#03872479).</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">About EDIT-301</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">EDIT-301 is an experimental, autologous cell therapy medicine under investigation for the treatment of sickle cell disease. EDIT-301 is comprised of sickle patient CD34+ cells genetically modified using a highly specific and efficient CRISPR/Cas12a (also known as Cpf1) ribonucleoprotein (RNP) that targets the HBG1 and HBG2 promoters in the beta-globin locus where naturally occurring fetal hemoglobin (HbF) inducing mutations reside. Red blood cells derived from EDIT-301 CD34+ cells demonstrate a sustained increase in HbF production, which has the potential to provide a durable treatment benefit for people living with sickle cell disease.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">About RUBY</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">The RUBY Trial is a single-arm, open-label, multi-center Phase 1/2 study designed to assess the safety and efficacy of EDIT-301 in patients with severe sickle cell disease. Enrolled patients will receive a single administration of EDIT-301. </font><font style="font-size:12pt;">Additional details are available on www.clinicaltrials.gov (NCT#04853576).</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Forward-Looking Statements</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;white-space:pre-wrap;">This press release contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words &#8216;&#8216;anticipate,&#8217;&#8217; &#8216;&#8216;believe,&#8217;&#8217; &#8216;&#8216;continue,&#8217;&#8217; &#8216;&#8216;could,&#8217;&#8217; &#8216;&#8216;estimate,&#8217;&#8217; &#8216;&#8216;expect,&#8217;&#8217; &#8216;&#8216;intend,&#8217;&#8217; &#8216;&#8216;may,&#8217;&#8217; &#8216;&#8216;plan,&#8217;&#8217; &#8216;&#8216;potential,&#8217;&#8217; &#8216;&#8216;predict,&#8217;&#8217; &#8216;&#8216;project,&#8217;&#8217; &#8216;&#8216;target,&#8217;&#8217; &#8216;&#8216;should,&#8217;&#8217; &#8216;&#8216;would,&#8217;&#8217; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements regarding the initiation, timing, progress and results of the Company&#8217;s preclinical and clinical studies and its research and development programs, including beginning patient dosing in the RUBY trial by the end of 2021, the timing for the Company&#8217;s receipt and presentation of data from its clinical trials and preclinical studies, including presenting data from the first two cohorts of the BRILLIANCE trial by the end of 2021, and the timing or likelihood of regulatory filings and approvals, including filing an IND for EDIT-301 for the treatment of beta-thalassemia by the end of 2021. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in the initiation and completion of pre-clinical studies and clinical trials and clinical development of the Company&#8217;s product candidates; availability and timing of results from pre-clinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products and availability of funding sufficient for the Company&#8217;s foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater detail under the caption &#8220;Risk Factors&#8221; included in the Company&#8217;s most recent Annual Report on Form 10-K, which is on file with the Securities and Exchange Commission, and in other filings that the Company may make with the Securities and Exchange Commission in the future.  Any forward-looking statements contained in this press release represent Company&#8217;s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, the Company explicitly disclaims any obligation to update any forward-looking statements.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">EDITAS MEDICINE, INC.</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Condensed Consolidated Statements of Operations</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">(unaudited)</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">(amounts in thousands, except per share and share data)</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:13.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:13.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;width:32.73%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Three Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:63.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;width:32.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">March 31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:63.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:14.92%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:14.94%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:63.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="font-size:12pt;">Collaboration and other research and development revenues</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.44%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">$</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:13.48%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="font-size:12pt;">6,499</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.44%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">$</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:13.5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="font-size:12pt;">5,723</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:63.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="font-size:12pt;">Operating expenses:</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:63.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 21.59pt;"><font style="font-size:12pt;">Research and development</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:13.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="font-size:12pt;">41,937</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:13.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="font-size:12pt;">34,570</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:63.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 21.59pt;"><font style="font-size:12pt;">General and administrative</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:13.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="font-size:12pt;">21,445</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:13.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="font-size:12pt;">17,769</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:63.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 21.59pt;"><font style="font-size:12pt;">Total operating expenses</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.44%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:13.48%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="font-size:12pt;">63,382</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.44%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:13.5%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="font-size:12pt;">52,339</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.65%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:63.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="font-size:12pt;">Operating loss</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.44%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:13.48%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">(56,883)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.44%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:13.5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">(46,616)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:63.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 21.59pt;"><font style="font-size:12pt;">Other income, net:</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:63.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 21.59pt;"><font style="font-size:12pt;">Other income (expense), net</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:13.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="font-size:12pt;">21</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:13.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="font-size:12pt;">7,333</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:63.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 21.59pt;"><font style="font-size:12pt;">Interest income, net</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:13.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="font-size:12pt;">134</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:13.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="font-size:12pt;">1,559</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.65%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:63.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="font-size:12pt;">Total other income, net</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.44%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:13.48%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="font-size:12pt;">155</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.44%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:13.5%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="font-size:12pt;">8,892</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:63.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="font-size:12pt;">Net loss</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.44%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">$</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:13.48%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">(56,728)</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.86%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.44%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">$</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:13.5%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">(37,724)</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.65%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:63.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="font-size:12pt;">Net loss per share attributable to common stockholders, basic and diluted</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.44%;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">$</font></p></td><td style="vertical-align:bottom;width:13.48%;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">(0.86)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.44%;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">$</font></p></td><td style="vertical-align:bottom;width:13.5%;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">(0.69)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:63.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="font-size:12pt;">Weighted-average common shares outstanding, basic and diluted</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.44%;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:13.48%;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="font-size:12pt;">65,992,395</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.86%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.44%;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:13.5%;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="font-size:12pt;">54,590,194</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.65%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">EDITAS MEDICINE, INC.</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Selected Condensed Consolidated Balance Sheet Items</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">(unaudited) </b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">(amounts in thousands)</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:11.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:15.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:62.05%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">March&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:18.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">December&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:62.05%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:12.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:18.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:62.05%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:12.86%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:18.12%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.05%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="font-size:12pt;">Cash, cash equivalents, and marketable securities</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">$</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="font-size:12pt;">723,223</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">$</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:15.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="font-size:12pt;">511,774</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:62.05%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="font-size:12pt;">Working capital</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="font-size:12pt;">568,305</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:15.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="font-size:12pt;">358,894</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.05%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="font-size:12pt;">Total assets</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="font-size:12pt;">780,294</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:15.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="font-size:12pt;">572,602</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:62.05%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="font-size:12pt;">Deferred revenue, net of current portion</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="font-size:12pt;">56,667</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:15.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="font-size:12pt;">73,984</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.05%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="font-size:12pt;">Total stockholders&#8217; equity</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="font-size:12pt;">637,996</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:15.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="font-size:12pt;">393,586</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Contacts:</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Media</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Cristi Barnett</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">(617) 401-0113</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">cristi.barnett@editasmed.com</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Investors</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Ron Moldaver</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">(617) 401-9052</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">ir@editasmed.com</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>edit-20210505xex99d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 edit-20210505xex99d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !I /(# 2(  A$! Q$!_\0
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MWO&"J8LAE)Z9JYXRG!I.^JOZ>I,<-.2;730XM/@=;"0%]=E9,\A;8 _GN/\
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#!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>edit-20210505.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7713.40453 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/5/2021 11:10:19 AM-->
<!--Modified on: 5/5/2021 11:10:19 AM-->
<xsd:schema targetNamespace="http://www.editasmedicine.com/20210505" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:attributeFormDefault="unqualified" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:edit="http://www.editasmedicine.com/20210505">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="edit-20210505_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="edit-20210505_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>edit-20210505_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7713.40453 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/5/2021 11:10:19 AM-->
<!--Modified on: 5/5/2021 11:10:19 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cover [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Written Communications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Soliciting Material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Issuer Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>edit-20210505_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7713.40453 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/5/2021 11:10:19 AM-->
<!--Modified on: 5/5/2021 11:10:19 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="edit-20210505.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType_637558098190994220" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_637558098190994220" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_637558098190994220" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_637558098190994220" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_637558098190994220" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_637558098190994220" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_637558098190994220" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_637558098190994220" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_637558098190994220" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_637558098190994220" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_637558098190994220" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_637558098190994220" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_637558098190994220" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_637558098190994220" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_637558098190994220" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_637558098190994220" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_637558098190994220" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_637558098190994220" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_637558098191004216" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_637558098191004216" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_637558098191004216" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_637558098191004216" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_637558098191004216" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_637558098191004216" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_637558098191004216" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications_637558098191004216" order="13" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_637558098191004216" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial_637558098191004216" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_637558098191004216" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer_637558098191004216" order="15" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_637558098191004216" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer_637558098191004216" order="16" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_637558098191004216" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_637558098191004216" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_637558098191004216" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_637558098191004216" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_637558098191004216" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_637558098191004216" order="19" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_637558098191004216" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_637558098191004216" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_637558098191014256" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_637558098191014256" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_637558098191014256" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_637558098191014256" order="22" use="optional" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>edit-20210505x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="edit-20210505.xsd" xlink:type="simple"/>
    <context id="Duration_5_5_2021_To_5_5_2021_MBYEzrXtsUi8fNw4j4D2GA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
        </entity>
        <period>
            <startDate>2021-05-05</startDate>
            <endDate>2021-05-05</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="Duration_5_5_2021_To_5_5_2021_MBYEzrXtsUi8fNw4j4D2GA"
      id="Tc_q9dD23vZrUON_Hf75eALCA_2_1">0001650664</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_5_5_2021_To_5_5_2021_MBYEzrXtsUi8fNw4j4D2GA"
      id="Tc_bYrzDBsVZkiPSPtM5pTfUA_3_1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_5_5_2021_To_5_5_2021_MBYEzrXtsUi8fNw4j4D2GA"
      id="Narr_pEPL-AusAEazQkJD_Tq3Vw">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_5_5_2021_To_5_5_2021_MBYEzrXtsUi8fNw4j4D2GA"
      id="Narr_Au1VlgZ400KJoxoWE_ofcw">2021-05-05</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="Duration_5_5_2021_To_5_5_2021_MBYEzrXtsUi8fNw4j4D2GA"
      id="Narr_JIbw_Qym00uNRK9VZBbOyQ">Editas Medicine, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_5_5_2021_To_5_5_2021_MBYEzrXtsUi8fNw4j4D2GA"
      id="Tc_xUoyjBFYkE26lDeSaJCddg_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="Duration_5_5_2021_To_5_5_2021_MBYEzrXtsUi8fNw4j4D2GA"
      id="Tc_-lHpZc4Dr0y2MKeb44oL6g_1_1">001-37687</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_5_5_2021_To_5_5_2021_MBYEzrXtsUi8fNw4j4D2GA"
      id="Tc_DvVqKeUvs0OmElHftDtBEQ_1_2">46-4097528</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_5_5_2021_To_5_5_2021_MBYEzrXtsUi8fNw4j4D2GA"
      id="Narr_js3KQso40USdR7ZeqH-E0A">11 Hurley Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_5_5_2021_To_5_5_2021_MBYEzrXtsUi8fNw4j4D2GA"
      id="Narr_g7TL0ow-zEO586YTQ1Xf6Q">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_5_5_2021_To_5_5_2021_MBYEzrXtsUi8fNw4j4D2GA"
      id="Narr_HX29x--sOk-gbibPIBlU4g">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_5_5_2021_To_5_5_2021_MBYEzrXtsUi8fNw4j4D2GA"
      id="Tc_4_aWokmZHE2cubNtm1YJ2g_1_1">02141</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_5_5_2021_To_5_5_2021_MBYEzrXtsUi8fNw4j4D2GA"
      id="Narr_CbZuv00c20ubk9XbIIqxag">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_5_5_2021_To_5_5_2021_MBYEzrXtsUi8fNw4j4D2GA"
      id="Narr_eT-J-PD7uUK4CIzVkQuI6Q">401-9000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="Duration_5_5_2021_To_5_5_2021_MBYEzrXtsUi8fNw4j4D2GA"
      id="Tc_CkVI6dyNlEiX6mJd-CSbYA_2_0">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_5_5_2021_To_5_5_2021_MBYEzrXtsUi8fNw4j4D2GA"
      id="Tc_6GWmEnN4IU-dU028cxfakw_4_0">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_5_5_2021_To_5_5_2021_MBYEzrXtsUi8fNw4j4D2GA"
      id="Tc_0AxH5jlQ-UWTIoAv-WK--Q_6_0">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_5_5_2021_To_5_5_2021_MBYEzrXtsUi8fNw4j4D2GA"
      id="Tc_vM0GyLe4oUeSMrEAiXFHcg_8_0">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="Duration_5_5_2021_To_5_5_2021_MBYEzrXtsUi8fNw4j4D2GA"
      id="Tc_6cyLafhnY0q4-fsQBtYmiQ_2_0">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_5_5_2021_To_5_5_2021_MBYEzrXtsUi8fNw4j4D2GA"
      id="Tc_18dKrF0lp06X5e2LNGMT0Q_2_1">EDIT</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_5_5_2021_To_5_5_2021_MBYEzrXtsUi8fNw4j4D2GA"
      id="Tc_A54GCkrxVU-2h0ue2S1kaQ_2_2">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_5_5_2021_To_5_5_2021_MBYEzrXtsUi8fNw4j4D2GA"
      id="Narr_Yj6orePdAUuxey9rO1j1Cg">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139699977724728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>May 05, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May  05,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37687<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Editas Medicine, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-4097528<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">11 Hurley Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02141<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">401-9000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EDIT<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001650664<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( $XYI5('04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " !..:52K,K\B>\    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+/
M2L0P$(=?17)O)^GB'T(W%\63@N""XBTDL[MAFR8D(^V^O6G=[2+Z $(NF?GE
MFV\@K8G2A(0O*41,Y#!?C;[KLS1QS?9$40)DLT>O<UT2?6EN0_*:RC7M(&IS
MT#N$AO,;\$C::M(P :NX$)EJK9$FH::03GAK%GS\3-T,LP:P0X\]91"U *:F
MB?$X=BU< !.,,/G\74"[$.?JG]BY ^R4'+-;4L,PU,-JSI4=!+P_/[W.ZU:N
MSZ1[@^55=I*.$=?L//EM=?^P>62JX8VH^'4Y&WXK!9?-W<?D^L/O(NR#=5OW
MCXW/@JJ%7_]"?0%02P,$%     @ 3CFE4IE<G",0!@  G"<  !,   !X;"]T
M:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M
M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R
M>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2P]R"BPA+>!3+
MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!
M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K
MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2
MBW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_KFVB<"HU;3]-K
M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M#Q\:(MXIR3JHWJ$('D3"R5.>+KBN8\(U?)]>7/6Z_1["TRUYNN?P//.5<#4
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M<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ 3CFE4APX9>H_ 0  / (
M  \   !X;"]W;W)K8F]O:RYX;6R-4<MNPD ,_)75?D 34(M41+B4/I"J%I6*
M^Y)UB,4^(J\#+5]?)U%4I%YZ\GILC6=F%^=(QWV,1_7E74B%KIF;>9:EL@9O
MTDUL(,BDBN0-2TN'+#4$QJ8:@+W+IGD^R[S!H)>+D6M#V743&4K&& 3L@!W"
M.?W.NU:=,.$>'?)WH?NW ZT\!O1X 5OH7*M4Q_-+)+S$P,9M2XK.%7HR#'9
MC.4?>-N)_#3[U"-L]A]&A!1ZE@MAA92XW^CYC6@\@2P/7<OQ"1T#K0S#,\6V
MP7#H:,1%=F6CSV&L0XAS^D^,L:JPA%4L6P^!AQP)7"<PI!J;I%4P'@H]KB@3
MK'H,+"&I=1BH9+=S*J?7=G#-(O<J0YJC#&AM!^&C6@L5!K!O<B )+LF5&U)=
MZ7FFMW>3>TFH=>Y!L/?P&HT=S8\?M_P!4$L#!!0    ( $XYI5(D'INBK0
M /@!   :    >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'.UD3T.@S ,A:\2
MY0 U4*E#!4Q=6"LN$ 7S(Q(2Q:X*MR^% 9 Z=&&RGBU_[\E.GV@4=VZ@MO,D
M1FL&RF3+[.\ I%NTBB[.XS!/:A>LXEF&!KS2O6H0DBBZ0=@S9)[NF:*<//Y#
M='7=:7PX_;(X\ \PO%WHJ45D*4H5&N1,PFBV-L%2XLM,EJ*H,AF**I9P6B#B
MR2!M:59]L$].M.=Y%S?W1:[-XPFNWPQP>'3^ 5!+ P04    " !..:5299!Y
MDAD!  #/ P  $P   %M#;VYT96YT7U1Y<&5S72YX;6RMDTU.PS 0A:\295LE
M+BQ8H*8;8 M=< %C3QJK_I-G6M+;,T[:2J 2%85-K'C>O,^>EZS>CQ&PZ)WU
MV)0=47P4 E4'3F(=(GBNM"$Y2?R:MB)*M9-;$/?+Y8-0P1-XJBA[E.O5,[1R
M;ZEXZ7D;3?!-F<!B63R-PLQJ2AFC-4H2U\7!ZQ^4ZD2HN7/08&<B+EA0BJN$
M7/D=<.I[.T!*1D.QD8E>I6.5Z*U .EK >MKBRAE#VQH%.JB]XY8:8P*IL0,@
M9^O1=#%-)IXPC,^[V?S!9@K(RDT*$3FQ!'_'G2/)W55D(TADIJ]X(;+U[/M!
M3EN#OI'-X_T,:3?D@6)8YL_X>\87_QO.\1'"[K\_L;S63AI_YHOA/UY_ 5!+
M 0(4 Q0    ( $XYI5('04UB@0   +$    0              "  0    !D
M;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ 3CFE4JS*_(GO    *P(  !$
M             ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @
M3CFE4IE<G",0!@  G"<  !,              ( !S0$  'AL+W1H96UE+W1H
M96UE,2YX;6Q02P$"% ,4    " !..:52+SL- 3<$  !'$   &
M    @($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @
M3CFE4I^@&_"Q @  X@P   T              ( !>PP  'AL+W-T>6QE<RYX
M;6Q02P$"% ,4    " !..:52EXJ[',     3 @  "P              @ %7
M#P  7W)E;',O+G)E;'-02P$"% ,4    " !..:52'#AEZC\!   \ @  #P
M            @ % $   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ 3CFE
M4B0>FZ*M    ^ $  !H              ( !K!$  'AL+U]R96QS+W=O<FMB
M;V]K+GAM;"YR96QS4$L! A0#%     @ 3CFE4F60>9(9 0  SP,  !,
M         ( !D1(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^
) @  VQ,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="edit-20210505x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="edit-20210505x8k.htm">edit-20210505x8k.htm</File>
    <File>edit-20210505.xsd</File>
    <File>edit-20210505_lab.xml</File>
    <File>edit-20210505_pre.xml</File>
    <File>edit-20210505xex99d1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "edit-20210505x8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "edit-20210505x8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "edit-20210505_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "edit-20210505_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "edit-20210505.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "edit",
   "nsuri": "http://www.editasmedicine.com/20210505",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20210505x8k.htm",
      "contextRef": "Duration_5_5_2021_To_5_5_2021_MBYEzrXtsUi8fNw4j4D2GA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "role": "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20210505x8k.htm",
      "contextRef": "Duration_5_5_2021_To_5_5_2021_MBYEzrXtsUi8fNw4j4D2GA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001558370-21-005794-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-21-005794-xbrl.zip
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M;>T]:7?:NK;?[UKO/^CEO'.;WA4;V]AF2)J[")"$)I !R- O+-F6P<78Q$.
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MD*@T#-"082'#<U&Y!]X\<;Y^,G[(^)$;GQ,+6"%YB$B)+'9$A<]UL$#4#J^
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M-7WKI<3\,WR!DJ8YQ'6CCU/#(GPB*_73S9Y<N+;(M9O:9>X'N3MFJEQI/2^
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MDH=51(L<J>,JTO>H"&>YA2LT][:A/;) ,\O1*+8V@8^>-S#W_Q]02P,$%
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MVJ[@P5%718/CR0FFO3E,WNLI/RKWN"?=T=%O)X'D[F^EW[X(]U9$TN;P>PA
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M@V,'K>1DG6;^J@;-G%[^FE69:2 #.*:,KV#,GJON$D@F?Y=1U!UU \%ORG<
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MR@RTF0I*3CN1YJ;=6NXCZFNJI7Q?E'6G"=Z+1'#$;Y5TC$[0;I/18(H;C)Z
M0-CO*F<$/P:1YW[X_U!+ 0(4 Q0    ( $XYI5*\E]K'3 ,  ,L+   1
M          "  0    !E9&ET+3(P,C$P-3 U+GAS9%!+ 0(4 Q0    ( $XY
MI5)AG6KE:04  &0\   5              "  7L#  !E9&ET+3(P,C$P-3 U
M7VQA8BYX;6Q02P$"% ,4    " !..:52IOR0.94$   L)P  %0
M    @ $7"0  961I="TR,#(Q,#4P-5]P<F4N>&UL4$L! A0#%     @ 3CFE
M4M<&HDP>%@  @8H  !0              ( !WPT  &5D:70M,C R,3 U,#5X
M.&LN:'1M4$L! A0#%     @ 3CFE4OLEB"_6)0  %GT! !@
M ( !+R0  &5D:70M,C R,3 U,#5X97@Y.60Q+FAT;5!+!08     !0 % $T!
(   [2@     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
